 CAMBRIDGE, Mass.--BUSINESS WIRE--Today, Sage Therapeutics, Inc. Nasdaq: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the second quarter ended June 30, 2021. Sage has made incredible progress on our mission to become the leader in brain health in the first half of 2021, setting us up for multiple near-mid and long-t 